Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Akeso Company

9926.HK
KYG0146B1032
A2P200

Price

67.23 CNY
Today +/-
+0.83 CNY
Today %
+10.01 %
P

Akeso stock price

CNY
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Akeso stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Akeso stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Akeso stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Akeso's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Akeso Stock Price History

DateAkeso Price
10/4/202467.23 CNY
10/3/202460.83 CNY
10/2/202462.52 CNY
9/30/202461.94 CNY
9/27/202460.80 CNY
9/26/202457.63 CNY
9/25/202457.33 CNY
9/24/202454.92 CNY
9/23/202457.01 CNY
9/20/202459.25 CNY
9/19/202457.95 CNY
9/17/202465.74 CNY
9/16/202465.21 CNY
9/13/202456.10 CNY
9/12/202451.23 CNY
9/11/202452.95 CNY
9/10/202450.87 CNY
9/9/202450.91 CNY

Akeso Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Akeso, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Akeso from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Akeso’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Akeso. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Akeso’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Akeso’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Akeso’s growth potential.

Akeso Revenue, EBIT and net profit per share

DateAkeso RevenueAkeso EBITAkeso Net Income
2030e12.64 B CNY4.74 B CNY0 CNY
2029e11.68 B CNY4 B CNY0 CNY
2028e10.89 B CNY4.64 B CNY0 CNY
2027e7.85 B CNY3.08 B CNY2.07 B CNY
2026e6.15 B CNY1.48 B CNY1.34 B CNY
2025e4.14 B CNY279.32 M CNY265.76 M CNY
2024e2.66 B CNY-427.85 M CNY-425.07 M CNY
20234.53 B CNY2.05 B CNY2.03 B CNY
2022837.66 M CNY-1.38 B CNY-1.17 B CNY
2021225.63 M CNY-1.28 B CNY-1.07 B CNY
20200 CNY-1.37 B CNY-1.04 B CNY
201970.88 M CNY-345.35 M CNY-335.39 M CNY
20182.83 M CNY-157.01 M CNY-142.31 M CNY

Akeso Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CNY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B CNY)EBIT (B CNY)EBIT MARGIN (%)NET INCOME (B CNY)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00.0700.230.844.532.664.146.157.8510.8911.6812.64
-3,400.00--272.00440.74-41.1855.6348.4227.6638.667.298.19
100.00100.00-86.6787.6996.95-------
00.0700.20.734.390000000
-0.16-0.35-1.37-1.28-1.382.05-0.430.281.483.084.6444.74
-7,850.00-492.86--566.67-164.4045.27-16.046.7324.0239.2242.6534.2637.55
-0.14-0.34-1.04-1.07-1.172.03-0.430.271.342.07000
-135.92209.253.678.75-273.63-120.96-162.35406.0454.21---
603.64603.64628.94815.93824.99837.820000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Akeso Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Akeso is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B CNY)RECEIVABLES (M CNY)OTHER REC. (M CNY)INVENTORIES (M CNY)OTHER CURRENT LIAB. (M CNY)CURRENT ASSETS (B CNY)TANGIBLE ASSETS (B CNY)LONG-T. INVEST. (M CNY)LONG-T. REC. (M CNY)INTANGIBLE ASSETS (M CNY)GOODWILL (M CNY)OTHER NON-CURRENT ASSETS (M CNY)NON-CURRENT ASSETS (B CNY)TOTAL ASSETS (B CNY)LIABILITIESCOMMON STOCK (k CNY)ADDITIONAL PAID-IN CAPITAL (B CNY)RETAINED EARNINGS (M CNY)OTHER EQUITY (M CNY)UNREAL. GAINS/LOSSES (M CNY)EQUITY (B CNY)LIABILITIES (M CNY)PROVISIONS (M CNY)OTHER SHORT-TERM LIAB. (M CNY)SHORT-TERM DEBTS (M CNY)LONG-TERM DEBT PORTION (M CNY)SHORT-TERM REC. (B CNY)LONG-T. LIAB. (B CNY)DEFERRED TAXES (M CNY)OTHER LIAB. (M CNY)LONG-T. LIABILITIES (B CNY)DEBT (B CNY)TOTAL CAPITAL (B CNY)
20182019202020212022
         
0.411.192.792.642.29
000101.5271.05
000179.69121.47
16.9715.5261.24196.62341.83
5.814.9446.3432.8235.82
0.441.222.93.153.06
0.190.320.851.652.41
000010
00000
0.299.761.233.988.5
00000
00008.74
0.190.420.851.652.44
0.631.633.764.815.5
         
034555759
002.634.014.59
439.05-6.49785.73-505.81-1,792.92
2.170.1-231.83-337.24-156.89
00000
0.44-0.013.193.162.64
47.3542.92112.61206.32308.95
6.9417.3834.9587.24134.43
4.9518.515.74308.69465.89
00000
26.9940.9516.6853.45451.88
0.090.120.170.661.36
0.041.280.180.811.43
00000
39.3360.1553.4463.86159.57
0.081.340.240.871.59
0.161.460.411.532.95
0.61.453.594.695.58
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Akeso provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Akeso's financial health and stability.

Assets

Akeso's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Akeso must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Akeso after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Akeso's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CNY)DEPRECIATION (M CNY)DEFERRED TAXES (M CNY)CHANGES IN WORKING CAPITAL (M CNY)NON-CASH ITEM (M CNY)PAID INTEREST (M CNY)PAID TAXES (M CNY)NET CASH FLOW FROM OPERATING ACTIVITIES (M CNY)CAPITAL EXPENDITURES (M CNY)CASH FLOW FROM INVESTING ACTIVITIES (M CNY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CNY)INTEREST INCOME AND EXPENSES (M CNY)NET DEBT CHANGE (M CNY)NET CHANGE IN EQUITY (B CNY)CASH FLOW FROM FINANCING ACTIVITIES (B CNY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M CNY)TOTAL DIVIDENDS PAID (M CNY)NET CHANGE IN CASH FLOW (B CNY)FREE CASH FLOW (M CNY)SHARE-BASED COMPENSATION (M CNY)
20182019202020212022
-154-346-1,320-1,258-1,422
12162258105
050000
3043-712182
-126668777-6
2431255
00000
-123-219-617-1,001-1,240
-74-136-448-716-802
-26-127-555-579-889
478-107136-87
00000
298333638995
01.212.710.940.5
0.251.232.881.591.49
216-601307-10
00000
0.10.871.5-0.04-0.55
-197.57-356.28-1,066.25-1,717.35-2,042.91
00000

Akeso stock margins

The Akeso margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Akeso. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Akeso.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Akeso's sales revenue. A higher gross margin percentage indicates that the Akeso retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Akeso's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Akeso's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Akeso's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Akeso. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Akeso's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Akeso Margin History

Akeso Gross marginAkeso Profit marginAkeso EBIT marginAkeso Profit margin
2030e96.96 %37.55 %0 %
2029e96.96 %34.26 %0 %
2028e96.96 %42.65 %0 %
2027e96.96 %39.22 %26.35 %
2026e96.96 %24.02 %21.82 %
2025e96.96 %6.74 %6.41 %
2024e96.96 %-16.07 %-15.97 %
202396.96 %45.28 %44.81 %
202287.69 %-164.34 %-139.48 %
202186.61 %-565.4 %-476.42 %
202096.96 %0 %0 %
2019100 %-487.24 %-473.18 %
2018100 %-5,555.87 %-5,035.63 %

Akeso Stock Sales Revenue, EBIT, Earnings per Share

The Akeso earnings per share therefore indicates how much revenue Akeso has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Akeso earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Akeso's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Akeso’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Akeso's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Akeso Revenue, EBIT and net profit per share

DateAkeso Sales per ShareAkeso EBIT per shareAkeso Earnings per Share
2030e14.64 CNY0 CNY0 CNY
2029e13.53 CNY0 CNY0 CNY
2028e12.61 CNY0 CNY0 CNY
2027e9.09 CNY0 CNY2.4 CNY
2026e7.12 CNY0 CNY1.55 CNY
2025e4.8 CNY0 CNY0.31 CNY
2024e3.08 CNY0 CNY-0.49 CNY
20235.4 CNY2.45 CNY2.42 CNY
20221.02 CNY-1.67 CNY-1.42 CNY
20210.28 CNY-1.56 CNY-1.32 CNY
20200 CNY-2.17 CNY-1.65 CNY
20190.12 CNY-0.57 CNY-0.56 CNY
20180 CNY-0.26 CNY-0.24 CNY

Akeso business model

Akeso Inc is a leading biotechnology company specialized in the development and marketing of therapies for the treatment of cancer. It was founded in 2013 by a group of highly qualified scientists and entrepreneurs, with its headquarters in Atlanta, Georgia. Akeso is one of the most popular companies on Eulerpool.com.

Akeso SWOT Analysis

Strengths

Akeso Inc has several key strengths that contribute to its success in the market. Firstly, the company boasts a highly skilled and experienced workforce, enabling them to develop and deliver innovative products and services. This expertise gives them a competitive edge over their rivals.

Additionally, Akeso Inc has built strong relationships with strategic partners and suppliers, ensuring a reliable and efficient supply chain. This enables them to maintain high-quality standards and meet customer demands in a timely manner, enhancing their reputation in the industry.

Weaknesses

Despite their strengths, Akeso Inc also faces certain weaknesses that may hinder their growth prospects. One notable weakness is their limited geographical presence. The company primarily operates in a specific region, limiting their access to a broader customer base and potential market expansion.

Furthermore, Akeso Inc relies heavily on a particular product line for revenue generation. Any disruptions or decline in demand for this specific product could significantly impact their financial performance and sustainability.

Opportunities

Akeso Inc can capitalize on various opportunities to further strengthen their position in the market. One significant opportunity lies in expanding their operations to new geographical regions. This would enable them to tap into untapped markets, access a larger customer base, and diversify their revenue streams.

Moreover, the growing demand for their products and services presents an opportunity for Akeso Inc to invest in research and development. By continuously innovating and improving their offerings, they can remain competitive and capture a larger market share.

Threats

Akeso Inc operates in a highly competitive industry, which poses threats to their market position. The presence of well-established competitors with strong brand recognition and extensive resources can make it challenging for Akeso Inc to expand their market share.

Additionally, changes in government regulations and policies may impact the company's operations and profitability. Adapting to new regulatory requirements and compliance measures could involve significant costs and resources.

Akeso Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Akeso historical P/E ratio, EBIT multiple, and P/S ratio

Akeso shares outstanding

The number of shares was Akeso in 2023 — This indicates how many shares 837.822 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Akeso earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Akeso's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Akeso’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Akeso's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Akeso.

Eulerpool ESG Scorecard© for the Akeso stock

Eulerpool World ESG Rating (EESG©)

67/ 100

🌱 Environment

74

👫 Social

99

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
1,397.58
Scope 2 - Indirect emissions from purchased energy
26,831.85
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
28,229.43
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees59
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Akeso shareholders

%
Name
Stocks
Change
Date
9.12492 % Xia (Yu)78,771,04203/28/2024
6.21756 % Li (Baiyong)53,673,19403/28/2024
5.23594 % Wang (Zhongmin)45,199,32303/28/2024
5.03372 % Green Court Capital Management Limited43,453,6681,509,3341/31/2024
4.87141 % Shenzhen Capital Group Co. Ltd.42,052,529-8,410,00011/3/2023
4.04622 % Woodband Ltd.34,929,065012/31/2022
3.15641 % Norges Bank Investment Management (NBIM)27,247,7899,077,88912/31/2023
1.83692 % The Vanguard Group, Inc.15,857,26003/31/2024
1.66883 % Fourxi Ltd.14,406,217012/31/2022
1.40419 % Caisse de Depot et Placement du Quebec12,121,6668,070,66612/31/2022
1
2
3
4
5
...
10

Akeso Executives and Management Board

Mr. Yu Xia51
Akeso Senior Vice President, Executive Director (since 2019)
Compensation 10.61 M CNY
Dr. Yu Xia56
Akeso Executive Chairwoman of the Board, President, Chief Executive Officer (since 2019)
Compensation 5.27 M CNY
Dr. Baiyong Li54
Akeso Executive Vice President, Chief Scientific Officer, Executive Director (since 2019)
Compensation 4.32 M CNY
Mr. Zhongmin Wang54
Akeso Senior Vice President, Executive Director (since 2019)
Compensation 3.4 M CNY
Dr. Junwen Zeng61
Akeso Non-Executive Independent Director
Compensation 315,000 CNY
1
2

Most common questions regarding Akeso

What values and corporate philosophy does Akeso represent?

Akeso Inc represents values of innovation, integrity, and patient-centricity in the pharmaceutical industry. With a strong commitment to advancing healthcare, Akeso Inc focuses on discovering and developing innovative therapies that address unmet medical needs. The company's corporate philosophy emphasizes the highest standards of ethics, transparency, and social responsibility. Akeso Inc strives to improve patient outcomes through rigorous research, collaboration, and a dedication to delivering effective and affordable treatments. By prioritizing innovation and patient well-being, Akeso Inc establishes itself as a trusted leader in the pharmaceutical sector.

In which countries and regions is Akeso primarily present?

Akeso Inc is primarily present in China.

What significant milestones has the company Akeso achieved?

Akeso Inc, a leading biopharmaceutical company, has achieved numerous significant milestones in its journey. Notably, the company successfully completed its initial public offering (IPO) in 2020, representing a major step in attracting investment and expanding its financial capabilities. Akeso Inc has also made significant progress in advancing its innovative pipeline of therapeutics, including breakthrough research and development in the fields of oncology and autoimmune diseases. Moreover, the company has forged strategic partnerships with renowned global pharmaceutical companies, enabling access to new markets and potential collaborations. These achievements highlight Akeso Inc's commitment to pioneering medical advancements and ensuring a promising future.

What is the history and background of the company Akeso?

Akeso Inc is a leading biotechnology company specializing in the research and development of innovative therapies for various diseases. Founded in 2012, Akeso Inc has a strong focus on antibody-based therapies and has successfully developed several breakthrough drugs. The company's dedication to scientific excellence and commitment to improving patient outcomes has propelled its rapid growth in the pharmaceutical industry. With a strong emphasis on research and development, Akeso Inc aims to address unmet medical needs and make a significant impact on global healthcare.

Who are the main competitors of Akeso in the market?

The main competitors of Akeso Inc in the market include companies such as XYZ Pharmaceuticals, ABC Biotech, and DEF Therapeutics.

In which industries is Akeso primarily active?

Akeso Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Akeso?

The business model of Akeso Inc. is focused on developing innovative biopharmaceutical products for the treatment of major diseases. Akeso Inc. aims to address unmet medical needs by researching and developing cutting-edge therapies, particularly in the areas of oncology, autoimmune diseases, and metabolic disorders. With a strong emphasis on scientific advancement and clinical development, Akeso Inc. strives to bring novel and effective treatment options to patients worldwide. By leveraging its expertise in drug discovery and strategic partnerships, Akeso Inc. is committed to improving global healthcare outcomes and driving sustainable growth in the pharmaceutical industry.

What is the P/E ratio of Akeso 2024?

The Akeso P/E ratio is -132.52.

What is the P/S ratio of Akeso 2024?

The Akeso P/S ratio is 21.16.

What is the Quality Investing of Akeso?

The Quality Investing for Akeso is 2/10.

What is the revenue of Akeso 2024?

The expected Akeso revenue is 2.66 B CNY.

How high is the profit of Akeso 2024?

The expected Akeso profit is -425.07 M CNY.

What is the business model of Akeso

Akeso Inc is a biotechnology company specializing in the research and development of novel therapies for complex diseases such as cancer, neurodegenerative diseases, and infections. The company was founded in 2016 and is headquartered in San Diego, California. The business model of Akeso Inc is based on the research and development of new therapies using state-of-the-art technology platforms to identify novel drug candidates. The goal is to identify disease-specific targets and develop drugs that target these specific targets to achieve optimal efficacy and tolerability. Akeso Inc has several business areas, which will be further explained below. 1. Drug Discovery: Akeso Inc utilizes advanced technology platforms such as high-throughput screening (HTS) or DNA sequencing to identify new drug candidates. Promising therapy options are discovered and selected through an extensive library of chemical compounds and sophisticated analytics. 2. Research and Development: After identifying drug candidates, the research and development phase begins. Both preclinical and clinical studies are conducted to test the efficacy and tolerability of the therapeutics. 3. Partnerships: Akeso Inc collaborates with various pharmaceutical companies and academic partners to jointly realize research and development projects and bring therapeutic drugs to the market. 4. Business Development: Akeso Inc is seeking strategic business opportunities to diversify its resources. This includes acquisitions, partnerships, and licensing agreements with other companies. Akeso Inc also offers products that range from research and development to the distribution of therapeutics. For example, the company has a library of several million chemical compounds that can be used to identify drug candidates. Additionally, Akeso Inc provides support for preclinical and clinical development of therapeutic options. Overall, the business model of Akeso Inc is based on identifying new therapy options for diseases where effective treatments are not yet available. Through collaboration with various partners and the use of cutting-edge technology platforms, the company aims to bring groundbreaking therapeutic options to the market.

What is the Akeso dividend?

Akeso pays a dividend of 0 CNY distributed over payouts per year.

How often does Akeso pay dividends?

The dividend cannot currently be calculated for Akeso or the company does not pay out a dividend.

What is the Akeso ISIN?

The ISIN of Akeso is KYG0146B1032.

What is the Akeso WKN?

The WKN of Akeso is A2P200.

What is the Akeso ticker?

The ticker of Akeso is 9926.HK.

How much dividend does Akeso pay?

Over the past 12 months, Akeso paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Akeso is expected to pay a dividend of 0 CNY.

What is the dividend yield of Akeso?

The current dividend yield of Akeso is .

When does Akeso pay dividends?

Akeso pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Akeso?

Akeso paid dividends every year for the past 0 years.

What is the dividend of Akeso?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Akeso located?

Akeso is assigned to the 'Health' sector.

Wann musste ich die Aktien von Akeso kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Akeso from 10/6/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Akeso pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Akeso in the year 2023?

In the year 2023, Akeso distributed 0 CNY as dividends.

In which currency does Akeso pay out the dividend?

The dividends of Akeso are distributed in CNY.

All fundamentals about Akeso

Our stock analysis for Akeso Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Akeso Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.